Conscience’s Post

Quick reminder that I'll be delivering a keynote at next week's Reuters Pharma EU in Barcelona titled “Pharma’s coming (r)evolution: How we unlock the promise of today’s 'Golden Age for Medicine.'"   With breakthroughs across so many categories thanks to better understanding of science, leaps in genomics and the use of AI in drug discovery, the future of medicine is here. Yet our industry is under unprecedented pressure to demonstrate the value of our therapies versus the prices they command.   So, what's happening? To solve this disconnect, our industry must evolve its approach to customer engagement and partnership to ensure this Golden Age of Medicine translates into the future of health we all want.   I'll be speaking 16 April. #REPharma2024 #pharma #futureofhealth

Delighted that both Marco Schmidt and Joern Klinger have agreed to join our Scientific Advisory Board. The strategic insights provided by AI powered causal modelling into clinical predictions really demonstrates the value of research pipelines to stakeholders such as investors. #clinicaltrials #clinicalresearch #drugdevelopment #forwardthinking

Looking forward to meeting you at the DDIF, which I will be attending with my colleague Volker A. Pfirsching. We expect interesting discussion on the use of data and AI to accelerate drug development. And if you were wondering why the Human Factor might be even more important than data when it comes to implementing AI and digital at scale you should definitely talk to us!

At Teva, being all in for better health, we're using AI to advance the drug development process: Improve the speed and accuracy of diagnosing medical conditions, accelerate clinical trial processes, and more – all so that we can get medicines to patients faster. One such example is Teva's involvement in the MOBILISE-D project, which focuses on conditions that often affect mobility, such as chronic obstructive pulmonary disease (COPD) and Parkinson’s disease. As Michal Melamed, Data Scientist, Advanced Analytics and AI at Teva, explains, “We are using AI and analytics to try to predict and assess the motor stage of the patients' disease, which affects the body’s movement, and to identify the walking factors most associated with Parkinson's disease motor stages.” Find out more about Teva’s innovative work in AI: https://lnkd.in/dFiikrfT #WorldHealthDay #Innovation #AI #AIinHealthcare #Tevapharm #WeAreAllInForBetterHealth

Disease won't wait for us to catch up. That's why we're using data tech to fundamentally disrupt traditional approaches to R&D - so we can understand human biology at different stages of disease and even in different patients to improve the chances of success. Here, Christopher Austin, Senior Vice President, Research Technologies at GSK, explains why giving researchers access to rich biological data at scale is crucial to accelerating drug discovery – and why a diverse skillset is needed to do this well and responsibly. 🔗 Discover how we’re innovating to reach patients better and faster: https://gsk.to/3RqT7Z3 👈 #LTW24 #LondonTechWeek

Teams from Fraunhofer ISST and Fraunhofer ITMP, University of Luxembourg, Johnson & Johnson and Lygature met in Dortmund for a deep-dive into the development status of the federated infrastructure, which is built in IDERHA. With federated learning, several players, such as clinics, pharmaceutical companies or research centers, are enabled to jointly train machine learning models without having to physically merge the data. IDERHA aims to demonstrate that this data-driven approach adds value for patients through data-driven disease management and decision making, as well as personalized treatment options. #patientengagement #datascience #AI #machinelearning #realworlddata #RWD #realworldevidence #RWE #datainfrastructure #dataaccess #remotemonitoring #healthdata #healthdataspace #healthpolicymaking #HTA #EHDS #lungcancer https://lnkd.in/e6CMck2Q

April 7th is World Health Day, and this year’s theme is ‘My health, my right’, championing the right of everyone, everywhere, to have access to health services, education and information. Like in so many other aspects of our lives, Artificial Intelligence (AI) and advanced analytics technologies have the potential to transform the world of healthcare. At Teva, being all in for better health, we're using AI to advance the drug development process: Improve the speed and accuracy of diagnosing medical conditions, accelerate clinical trial processes, and more – all so that we can get medicines to patients faster. One such example is Teva's involvement in the MOBILISE-D project, which focuses on conditions that often affect mobility, such as chronic obstructive pulmonary disease (COPD) and Parkinson’s disease. As Michal Melamed, Data Scientist, Advanced Analytics and AI at Teva, explains, “We are using AI and analytics to try to predict and assess the motor stage of the patients' disease, which affects the body’s movement, and to identify the walking factors most associated with Parkinson's disease motor stages.” Find out more about Teva’s innovative work in AI: https://lnkd.in/eUAV4aMb #WorldHealthDay #Innovation #AI #AIinHealthcare #Tevapharm #WeAreAllInForBetterHealth

At the PHUSE US Connect meeting on Feb 27, 2024, MMS data scientists Martin Bauwens and Kris Wenzel will discuss "The Need for AI-Facilitated Monitoring Methods and Techniques to Enhance Participant Safety and Welfare." This tool will be able to predict likely adverse events before they occur in clinical trials. By integrating AI with phenotypic specificity, this method transforms adverse event monitoring from a reactive process to a pre-emptive one. This forward-thinking approach in clinical trials utilizes AI to significantly improve participant safety. By analyzing phenotypic data with advanced algorithms, sponsors can detect unusual lab results that may indicate potential adverse events, marking a proactive departure from the conventional methods of relying on participant reports. This system not only facilitates the early identification of adverse events but also contributes to the refinement of medication development, addresses biases, and enhances participant diversity. The use of extensive clinical trial data, analyzed by AI and displayed in an easy-to-understand, color-coded format, simplifies the decision-making process for clinical teams. This represents a critical step forward in improving the safety and efficiency of clinical trials with the help of AI. Please join the presentation on Tuesday, 27th, at 2:30 PM. If you are interested in scheduling some time with the speakers and other leaders from MMS Data Science and Regulatory Affairs at booth 26, click here: https://hubs.li/Q02lBvcH0. #MMSCRO #DataScience #DrugDevelopment #phuse

 Think about it: chronic diseases, the silent thieves of health, often progress undetected between infrequent checkups.  PONS bridges this gap, capturing critical data on how diseases evolve in real time.  This goldmine of information is a boon for pharmaceutical companies, research hospitals, and key stakeholders in healthcare who want diverse, high-quality data on early-stage disease progress.  Imagine developing drugs with unprecedented precision, developing personalized medicine by collaborating with research scientists in hospitals by analyzing real-world disease progression data.  Faster clinical trials, targeted treatments, and ultimately, a new era of healthcare where we can intervene before diseases take hold.  PONS is not just a company, it's a healthcare revolution waiting to happen.  #NYCHealthInnovationWeek #HITLABSpring24Summit #HITLAB #AI #Digitalhealth

April 7th is World Health Day, and this year’s theme is ‘My health, my right’, championing the right of everyone, everywhere, to have access to health services, education and information. Like in so many other aspects of our lives, Artificial Intelligence (AI) and advanced analytics technologies have the potential to transform the world of healthcare. At Teva, being all in for better health, we're using AI to advance the drug development process: Improve the speed and accuracy of diagnosing medical conditions, accelerate clinical trial processes, and more – all so that we can get medicines to patients faster. One such example is Teva's involvement in the MOBILISE-D project, which focuses on conditions that often affect mobility, such as chronic obstructive pulmonary disease (COPD) and Parkinson’s disease. As Michal Melamed, Data Scientist, Advanced Analytics and AI at Teva, explains, “We are using AI and analytics to try to predict and assess the motor stage of the patients' disease, which affects the body’s movement, and to identify the walking factors most associated with Parkinson's disease motor stages.” Find out more about Teva’s innovative work in AI: https://lnkd.in/d58v9WnG #WorldHealthDay #Innovation #AI #AIinHealthcare #Tevapharm #WeAreAllInForBetterHealth